COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

CD19 CAR T-cells containing a Safety Switch to treat Relapsed /Refractoy Acute Lymphoblastic Leukemia

The purpose of this study is to establish a safe dose of study cells to give to patients with relapsed/ refractory ALL expressing CD19.

Age & Gender

3 years ~ 70 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Natalie Grover
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

16-1057

ClinicalTrials.gov

NCT03016377

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.